Dong S - Search Results

1

Novel nanomedicines to overcome cancer multidrug resistance.

Su Z, Dong S, Zhao SC, Liu K, Tan Y, Jiang X, Assaraf YG, Qin B, Chen ZS, Zou C. Su Z, et al. Among authors: dong s. Drug Resist Updat. 2021 Sep;58:100777. doi: 10.1016/j.drup.2021.100777. Epub 2021 Aug 4. Drug Resist Updat. 2021. PMID: 34481195 Review.

2

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.

Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, Zhang L, Chen ZS, Zou C. Song H, et al. Among authors: dong s. Signal Transduct Target Ther. 2020 Sep 8;5(1):193. doi: 10.1038/s41392-020-00300-w. Signal Transduct Target Ther. 2020. PMID: 32900991 Free PMC article. Review.

3

Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.

Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, Ke Z, Zou C, Chen ZS. Lei ZN, et al. Among authors: dong s. Pharmacol Ther. 2020 Dec;216:107672. doi: 10.1016/j.pharmthera.2020.107672. Epub 2020 Sep 8. Pharmacol Ther. 2020. PMID: 32910933 Free PMC article. Review.

4

Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.

Ma X, Guo J, Liu K, Chen L, Liu D, Dong S, Xia J, Long Q, Yue Y, Zhao P, Hu F, Xiao Z, Pan X, Xiao K, Cheng Z, Ke Z, Chen ZS, Zou C. Ma X, et al. Among authors: dong s. Mol Cancer. 2020 Oct 8;19(1):147. doi: 10.1186/s12943-020-01264-9. Mol Cancer. 2020. PMID: 33032611 Free PMC article.

5

Identification of CHRNB4 as a Diagnostic/Prognostic Indicator and Therapeutic Target in Human Esophageal Squamous Cell Carcinoma.

Li N, Liu K, Dong S, Ou L, Li J, Lai M, Wang Y, Bao Y, Shi H, Wang X, Wang S. Li N, et al. Among authors: dong s. Front Oncol. 2020 Nov 16;10:571167. doi: 10.3389/fonc.2020.571167. eCollection 2020. Front Oncol. 2020. PMID: 33304845 Free PMC article.

6

Mutational Pattern in Multiple Pulmonary Nodules Are Associated With Early Stage Lung Adenocarcinoma.

Dong SW, Li R, Cheng Z, Liu DC, Xia J, Xu J, Li S, Wang J, Yue Y, Fan Y, Cao Y, Dai L, Wang J, Zhao P, Wang X, Xiao Z, Qiu C, Wang GS, Zou C. Dong SW, et al. Front Oncol. 2021 Feb 19;10:571521. doi: 10.3389/fonc.2020.571521. eCollection 2020. Front Oncol. 2021. PMID: 33680914 Free PMC article.

7

Tepotinib hydrochloride for the treatment of non-small cell lung cancer.

Wu ZX, Li J, Dong S, Lin L, Zou C, Chen ZS. Wu ZX, et al. Among authors: dong s. Drugs Today (Barc). 2021 Apr;57(4):265-275. doi: 10.1358/dot.2021.57.4.3238323. Drugs Today (Barc). 2021. PMID: 33851690 Review.

8

Combining the Fecal Immunochemical Test with a Logistic Regression Model for Screening Colorectal Neoplasia.

Liu F, Long Q, He H, Dong S, Zhao L, Zou C, Wu W. Liu F, et al. Among authors: dong s. Front Pharmacol. 2021 Mar 17;12:635481. doi: 10.3389/fphar.2021.635481. eCollection 2021. Front Pharmacol. 2021. PMID: 33897424 Free PMC article.

9

Lurbinectedin for the treatment of small cell lung cancer.

Li L, Zou C, Dong S, Wu ZX, Ashby CR Jr, Chen ZS, Qiu C. Li L, et al. Among authors: dong s. Drugs Today (Barc). 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559. Drugs Today (Barc). 2021. PMID: 34151904 Review.

10

Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Xu L, et al. Among authors: dong s. J Hematol Oncol. 2022 Jul 7;15(1):87. doi: 10.1186/s13045-022-01307-2. J Hematol Oncol. 2022. PMID: 35799264 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,406 results

Search Page

Filters